antibodies inhibited angiogenesis in response to conditioned media from SOX11-positive cell lines. Thus, a SOX11-PDGFA paracrine angiogenesis axis has been discovered (see figure). In vivo modeling supported these results. In a final set of experiments, the authors show that SOX11-positive MCL primary tumors overexpress PDGFA and have increased microvessel densities, compared with SOX11-negative lymphomas. The therapeutic implications were shown in xenograft studies in which imatinib treatment reduced tumor growth and angiogenesis.

Taken together, these data demonstrate a new biologic role for SOX11 in the pathogenesis of MCL. SOX11 induces transcription of PDGFA which, in a paracrine manner, promotes angiogenesis and thus growth of the lymphoma. This may also explain the clinical features of indolent, nonnodal forms of MCL because the lack of SOX11 in these cases may be the reason for prolonged localization in blood, bone marrow, and spleen. These cells may still retain biologic characteristics of normal mantle cells because at least some cases of monoclonal B-cell lymphocytosis–like nonnodal MCL appear to have an “in situ” MCL pattern when gastrointestinal staging biopsies are performed.8

Although our understanding of the biology of SOX11 in MCL is significantly advanced through this article,1 questions still of course remain. Some controversy does exist regarding the prognostic relevance of SOX11 because some groups have reported SOX11 as a favorable factor, whereas others report it as an adverse factor.9,90 Careful analysis of inclusion criteria in such studies as well as further integrative studies to include the genomic mutational landscape will be required. However, from a therapeutic perspective, this opens a new avenue of investigation. The activity of lenalidomide in non-Hodgkin lymphomas including MCL may provide hints that angiogenesis is a relevant target given antiangiogenesis is one possible effect; however, the immunomodulatory and other putative actions of this drug cloud the issue. In light of this study, the inhibition of PDGFA signaling via any number of biological drugs is a logical next step. Such studies may help define the importance of this pathway in MCL, explore the relevance of assessing SOX11 expression as a predictive biomarker, and hopefully improve the outcome for patients with MCL.

**Conflict-of-interest disclosure:** The author declares no competing financial interests. ■

**REFERENCES**


© 2014 by The American Society of Hematology

---

**PLATELETS & THROMBOPOIESIS**

Comment on Yeung et al, page 2271

**Platelet 12-LOX scores a HIT**

**Alison H. Goodall, University of Leicester**

In this issue of *Blood*, Yeung et al provide evidence of a role for 12-lipoxygenase in platelet activation through FcγRIIa, which may provide a therapeutic target in heparin-induced thrombocytopenia (HIT).1

**HIT** can be a serious complication for patients receiving heparin, particularly in the context of surgery. Although relatively rare (affecting up to 5% of patients), the apparently paradoxical combination of thrombocytopenia and thrombosis seen in HIT can be life threatening. It is caused by heparin binding to platelet factor 4 (PF4) released from platelets, which in some patients can result in immune recognition of the structurally modified heparin-PF4 complexes. Binding of these immune complexes to the immunoglobulin (Ig)G Fc receptor on human platelets, FcγRIIa (CD32), results in their activation.2

FcγRIIa is 1 of 3 members of the immunoreceptor-based activatory motif (ITAM) family of tyrosine kinase signaling receptors in human platelets; the others are the glycoprotein VI collagen receptor and the recently discovered C-type lectin receptor 2.3 These differ in their signaling pathway from the G protein–coupled receptors (GPCRs) for all other platelet agonists such as thrombin, adenosine 5’-diphosphate (ADP), and thromboxane A2 (TXA2).

Activation via ITAMs leads not just to platelet aggregation and degranulation but also to formation of procoagulant platelets and the release of procoagulant microparticles (MPs). Hence, HIT is characterized by a fall in platelet numbers as they disintegrate and a release of platelet-derived MPs into the circulation that promote thrombin generation.4

The focus of the paper from Yeung et al is the role of platelet 12(S)-lipoxygenase (12-LOX) in platelet activation through FcγRIIa. Platelets have long been known to contain 12-LOX, but its role in platelet biology has remained elusive, unlike that of the other main platelet oxygenase cyclooxygenase-1 (COX-1). As is well known, COX-1 converts the arachidonic acid (AA) that is liberated from membrane phospholipids following activation, to the
platelet agonist TXA2, which on release activates platelets in an autocrine and paracrine manner through their thromboxane prostanoid (TP) receptors. Specific and irreversible inhibition of COX-1 by aspirin is a mainstay of antiplatelet therapy.

However, there is an alternative pathway for the metabolism of AA in the platelet, via 12-LOX, which metabolizes AA to 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid (12-HpETE). This is rapidly reduced to 12-hydroxyeicosatetraenoic acid (12-HETE) and released from the platelets in nanomolar quantities. 12-HETE is known to play a role in trans-cellular communication, but its role in platelets is less clear. Reports over the last 30 years have variously suggested that 12-HpETE and 12-HETE can either augment or inhibit platelet activation. Studies with 12-LOX inhibitors have also proved inconsistent, largely due to the lack of specificity.

Recently, medicinal chemists in Rockville and University of California, Santa Cruz have developed inhibitors that are selective for 12(S)-LOX over other lipoxigenases and cyclooxygenases. Holinstat’s group used these inhibitors to provide clear evidence for the involvement of 12-LOX in aggregation and degranulation of platelets activated by collagen as well as by ADP and thrombin, the latter via the protease-activated receptor (PAR) 4 receptor, but interestingly, not via PAR1. In the current paper, this group use one of these new inhibitors (ML355) to provide evidence that 12-LOX also plays an important role in the activation of platelets through FcγRIIa. They use 2 ligands known to activate platelets through FcγRIIa; a cross-linked anti-CD32 monoclonal antibody (mAb) and a CD9 mAb that binds to the CD9 antigen via its immunoglobulin Fab regions and to FcγRIIa via its Fc domain. Through a series of in vitro experiments in human platelets, they demonstrate that activation of GPIIb-IIIa (the platelet fibrinogen receptor) and consequent aggregation and degranulation are attenuated by ML355 via a mechanism that also affects phosphorylation of phospholipase C γ2 (PLCγ2), calcium mobilization, and phosphorylation of protein kinase C (PKC) and Ras-proximate-1 or Ras-related protein 1 (Rap1, key to activation of GPIIb-IIIa), while having no direct effect on phosphorylation of FcγRIIa itself. The reduced phosphorylation of Rap1 was confirmed in platelets from 12-LOX−/− mice, indicating that the effects were specific to 12-LOX.

Taken together, the data suggest that inhibition of 12-LOX may be a viable therapeutic target in patients with HIT. Preclinical testing of ML355 indicates a favorable pharmacological profile, and as 12-LOX appears, like TXA2 and ADP, to augment platelet activation, inhibiting 12-LOX may reduce rather than ablate the platelet response, predicting a favorable balance between thrombotic and bleeding risk. In addition, data from this group and others suggest a wider therapeutic potential because 12-LOX can also affect the response to collagen ADP and thrombin.

Many questions still remain. Importantly, although ML355 is shown to block generation of 12-HETE, it is unclear whether the effect of inhibiting 12-LOX on the platelet response to FcγRIIa is via 12-HETE, interacting with its recently identified receptor (GPCR31) (analogous to the role of TXA2) or via protein–protein interactions within the platelets, which is a reported mechanism of 12-LOX activity in other cells. It is known that platelet activation causes translocation of 12-LOX from the cytoplasm to the membrane, but its interacting partners are yet to be fully characterized. However, the rate of effect of ML355 on 12-LOX activity...
and the effects on the downstream signaling pathways of FcγRIIa favor an intracellular mechanism for 12-LOX either directly through PLCγ2 or via an upstream ITAM signaling complex (see figure).

What is important is that this is the first demonstration that 12-LOX is involved in platelet activation through the immune Fc receptor FcγRIIa and as such may provide a viable therapeutic target for patients with HIT. It is also worth noting our own observation that following infusion of heparin, there is a significant release of 12-HETE in vivo, despite aspirin therapy, suggesting 12-LOX may be even more intrinsically involved in the pathology of HIT. However, because 12-HETE has roles in other cells, the effect of inhibiting 12-LOX may have wider ranging effects that will be revealed through in vivo studies with inhibitors such as ML355.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES

9. Thomas CP, Morgan LT, Maskrey BH, et al. Jak2 is an intracellular tyrosine kinase that associates with hematopoietic cytokine receptors and is essential for mediating signaling by Tpo, erythropoietin, and in part also granulocyte colony-stimulating factor. Jak2 inhibitors can be used to suppress excess hematopoiesis in patients with myeloproliferative neoplasms, although at higher doses anemia and thrombocytopenia are frequently observed. Jak2 knockout mice die during embryogenesis due to absence of definitive erythropoiesis. Similarly, induced conditional knockout of Jak2 in adult hematopoiesis was lethal due to severe anemia due to Jak2 knockout in mature megakaryocytes and platelets. Jak2 knockouts are defective in platelet formation and thrombosis. It is also worth noting that Jak2 knockout in megakaryocytes and platelets results in an unexpected thrombocytosis phenotype. Their results demonstrate that Jak2 is dispensable for megakaryocyte differentiation and platelet formation but is required for suppressing circulating thrombopoietin (Tpo).

Model for the regulation of megakaryopoiesis and platelet numbers by Tpo. (A) Normal steady-state situation. Tpo (blue circles) is produced in the liver at a constant rate and reaches the bone marrow via the blood stream. Tpo enters the bone marrow microenvironment and binds to its receptor, Mpl (drawn in red), that is expressed on HSCs and megakaryocytic progenitors. Signaling requires the presence of Jak2 (green circles) and results in expansion of the HSCs and megakaryocytic progenitor pool. The megakaryocytic differentiation and polyploidization begins at the stage of promegakaryoblasts (pro-Meg) and ends with fully differentiated megakaryocytes (Meg), which deliver platelets (PLT) to the lumen of the blood vessels (yellow arrow). The bone marrow cells that express Mpl and platelets bind, internalize, and degrade Tpo, thereby lowering the available Tpo. (B) Megakaryocyte and platelet-specific knockout of Jak2. Expression of C4-recombinase driven by the Pf4 regulatory elements begins in late megakaryocytic progenitors and deletes Jak2 in megakaryocytes and platelets. Mpl expression remains normal throughout megakaryopoiesis, but Tpo cannot signal in late megakaryocytic cells or platelets. Mpl without Jak2 cannot efficiently remove and degrade Tpo. As a consequence, more Tpo is available in the bone marrow, leading to an expansion of HSCs, early megakaryocyte-biased progenitors, and colony-forming unit Meg. Thrombocytosis is observed in the peripheral blood.

© 2014 by The American Society of Hematology

Radek C. Skoda
UNIVERSITY HOSPITAL BASEL

In this issue of Blood, Meyer et al report that deleting Jak2 selectively in megakaryocytes and platelets results in an unexpected thrombocytosis phenotype. Their results demonstrate that Jak2 is dispensable for megakaryocyte differentiation and platelet formation but is required for suppressing circulating thrombopoietin (Tpo).

Jak2 is an intracellular tyrosine kinase that associates with hematopoietic cytokine receptors and is essential for mediating signaling by Tpo, erythropoietin, and in part also granulocyte colony-stimulating factor. Jak2 inhibitors can be used to suppress excess hematopoiesis in patients with myeloproliferative neoplasms, although at higher doses anemia and thrombocytopenia are frequently observed. Jak2 knockout mice die during embryogenesis due to absence of definitive erythropoiesis. Similarly, induced conditional knockout of Jak2 in adult hematopoiesis was lethal due to severe anemia...
Platelet 12-LOX scores a HIT

Alison H. Goodall